Cytosorbents Corporation
CTSO
$1.10
-$0.06-5.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.59M | 32.48M | 31.90M | 31.42M | 31.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.59M | 32.48M | 31.90M | 31.42M | 31.08M |
| Cost of Revenue | 10.47M | 9.25M | 8.34M | 8.35M | 9.13M |
| Gross Profit | 25.13M | 23.23M | 23.55M | 23.07M | 21.95M |
| SG&A Expenses | 35.06M | 36.69M | 37.96M | 38.63M | 38.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.44M | 55.52M | 57.78M | 60.61M | 63.24M |
| Operating Income | -16.85M | -23.05M | -25.88M | -29.19M | -32.15M |
| Income Before Tax | -22.41M | -20.22M | -27.08M | -29.09M | -30.06M |
| Income Tax Expenses | -1.69M | -813.70K | -813.70K | -813.70K | -813.70K |
| Earnings from Continuing Operations | -20.72 | -19.41 | -26.27 | -28.28 | -29.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.72M | -19.41M | -26.27M | -28.28M | -29.25M |
| EBIT | -16.85M | -23.05M | -25.88M | -29.19M | -32.15M |
| EBITDA | -15.28M | -21.48M | -24.29M | -27.59M | -30.69M |
| EPS Basic | -0.38 | -0.38 | -0.54 | -0.61 | -0.66 |
| Normalized Basic EPS | -0.26 | -0.25 | -0.35 | -0.39 | -0.42 |
| EPS Diluted | -0.38 | -0.38 | -0.54 | -0.61 | -0.66 |
| Normalized Diluted EPS | -0.26 | -0.25 | -0.35 | -0.39 | -0.42 |
| Average Basic Shares Outstanding | 217.74M | 209.57M | 199.49M | 189.20M | 178.62M |
| Average Diluted Shares Outstanding | 217.74M | 209.57M | 199.49M | 189.20M | 178.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |